The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2021 | Lacutamab for CTCL
Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, shares an overview of novel therapies which are currently under investigation for the treatment of cutaneous T-cell lymphoma (CTCL), highlighting the antibody therapy lacutamab which has demonstrated promising early results in the treatment of Sézary syndrome and mycosis fungoides. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
